By Sheeba M. | May 19, 2026
Trulieve’s Q2 Test: Can TRUL Defend Market Share Against Curaleaf?
Trulieve Cannabis is facing its most critical earnings call of 2026. After losing market-cap parity to Curaleaf last quarter, TRUL needs to prove it can grow revenue faster than competitors while maintaining EBITDA margins above 30%.
The stakes are existential: If same-store sales (SSS) growth dips below 8% or EBITDA margins fall below 28%, expect institutional investors to rotate into Green Thumb Industries and Curaleaf. That would open the door for a hostile bid or significant equity dilution from debt restructuring.
What to Watch:
- Florida organic growth (TRUL’s crown jewel): Targeting 15%+ SSS year-over-year
- Wholesale cost-per-unit trends: Every $2/unit increase flows to margins
- New market contribution: Texas, New Mexico, and Northeast expansion
- Executive commentary on M&A positioning: Will they defend independence or signal openness?
Trulieve’s survival narrative hinges on being the operator with the best unit economics. If they deliver that—combined with a credible path to 40+ states by 2028—the stock rebounds to $15+. If not, TRUL becomes an acquisition target before Q4.
Sources
- Trulieve Investor Relations — Q2 2026 earnings guidance and historical data
- SEC EDGAR — Recent 8-K filings and disclosures
- MSO Performance Tracker — Comparative EBITDA margins and SSS data
Track cannabis stocks with the Weedstock Real-Time Tracker